Physician profile
Astaad H Dalal
NPI 1184067522
$98,557.24
in general payments reported to CMS, 2019-2025
41 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $223 · 2021: $638 · 2022: $7,683 · 2023: $56K · 2024: $10K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Food and Beverage: $6,849 · Consulting Fee: $6,666 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,514 · Travel and Lodging: $2,299 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,226.88 |
| Food and Beverage | $6,849.36 |
| Consulting Fee | $6,666.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,514.00 |
| Travel and Lodging | $2,298.63 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $41,807.39 | 2022-2024 | Quviviq |
| Harmony Biosciences LLC | $34,970.61 | 2020-2025 | Wakix |
| Lilly USA, LLC | $15,432.01 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $1,072.31 | 2019-2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $789.32 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $608.52 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $453.93 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $409.65 | 2023-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $336.72 | 2019-2025 | |
| United Therapeutics Corporation | $292.42 | 2022-2025 | Tyvaso, Remodulin, Tyvaso |
| Amgen INC. | $229.91 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $227.52 | 2022-2025 | Glassia |
| Electromed, INC. | $214.78 | 2021-2025 | Smartvest |
| Mylan Specialty L.P. | $210.84 | 2020-2023 | Yupelri |
| Glaxosmithkline, LLC. | $198.76 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $155.40 | 2024-2025 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.28 | 2019-2024 | Spiriva Respimat, Ofev |
| Mallinckrodt Hospital Products INC. | $126.85 | 2023-2024 | Acthar |
| Philips North America LLC | $114.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $80.57 | 2025 | Zerbaxa |
| Grifols USA, LLC | $74.66 | 2021-2025 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $62.19 | 2021-2022 | |
| Zoll Respicardia, INC. | $54.98 | 2023-2024 | Remede System |
| 3b Medical, INC. | $53.89 | 2025 | Luna |
| Actelion Pharmaceuticals US, INC. | $47.23 | 2024 | Opsumit |
| Alexion Pharmaceuticals, INC. | $42.42 | 2022-2024 | Ultomiris |
| Viatris Specialty LLC | $33.95 | 2025 | Yupelri |
| Tempus Ai, INC | $28.85 | 2024 | |
| Vapotherm INC | $26.30 | 2022 | |
| Abbvie INC. | $25.66 | 2024 | |
| Novo Nordisk INC | $23.50 | 2023 | Ozempic, Rybelsus |
| Verona Pharma, INC. | $23.36 | 2025 | Ohtuvayre |
| Vanda Pharmaceuticals INC. | $22.44 | 2020 | |
| Vifor Pharma, INC. | $22.33 | 2024 | Zemaira |
| Pfizer INC. | $21.12 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $20.97 | 2025 | Dupixent |
| Insmed, INC. | $20.45 | 2019 | |
| Hikma Pharmaceuticals USA | $17.71 | 2024 | Ryaltris |
| Resmed Corp | $17.13 | 2021 | |
| Optinose US, INC. | $16.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Astaad Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.